e-learning
resources
Munich 2006
Monday 04.09.2006
Pulmonary hypertension: diagnostic tools and therapeutic approaches
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension
L. S. Mackay, J. O‘Sullivan, G. A. MacGowan, R. Allcock, A. J. Fisher, J. Lordan, P. A. Corris (Newcastle upon Tyne, United Kingdom)
Source:
Annual Congress 2006 - Pulmonary hypertension: diagnostic tools and therapeutic approaches
Session:
Pulmonary hypertension: diagnostic tools and therapeutic approaches
Session type:
Thematic Poster Session
Number:
2489
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. S. Mackay, J. O‘Sullivan, G. A. MacGowan, R. Allcock, A. J. Fisher, J. Lordan, P. A. Corris (Newcastle upon Tyne, United Kingdom). The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension. Eur Respir J 2006; 28: Suppl. 50, 2489
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study
Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018
Year: 2018
Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease
Source: Eur Respir Rev 2009; 18: 154-161
Year: 2009
Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Changing demographics of pulmonary arterial hypertension in congenital heart disease
Source: Eur Respir Rev 2010 19: 308-313
Year: 2010
The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD)
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004
Nebulised Iloprost for pulmonary arterial hypertension associated with congenital heart disease: one centre's experience
Source: Eur Respir J 2001; 18: Suppl. 33, 324s
Year: 2001
Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Pulmonary hypertension in children
Source: Eur Respir Mon 2012; 57: 94-107
Year: 2012
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Double combination therapy in patients with pulmonary arterial hypertension associated with congenital heart defects
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Efficacy of exercise training in congenital heart disease associated pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Age, risk and outcomes in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018
Year: 2018
Pulmonary arterial hypertension related with congenital heart disease (PAH r-CHD): a retrospective study of 21 patients
Source: Annual Congress 2009 - Pulmonary circulation
Year: 2009
Pulmonary arterial hypertension in children
Source: Eur Respir J 2003; 21: 155-176
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept